Suppr超能文献

扫描肽阵列分析确定了信号支架蛋白β-抑制蛋白和RACK1在cAMP特异性磷酸二酯酶PDE4D5中的重叠结合位点。

Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.

作者信息

Bolger Graeme B, Baillie George S, Li Xiang, Lynch Martin J, Herzyk Pawel, Mohamed Ahmed, Mitchell Lisa High, McCahill Angela, Hundsrucker Christian, Klussmann Enno, Adams David R, Houslay Miles D

机构信息

Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294-3300, USA.

出版信息

Biochem J. 2006 Aug 15;398(1):23-36. doi: 10.1042/BJ20060423.

Abstract

The cAMP-specific phosphodiesterase PDE4D5 can interact with the signalling scaffold proteins RACK (receptors for activated C-kinase) 1 and beta-arrestin. Two-hybrid and co-immunoprecipitation analyses showed that RACK1 and beta-arrestin interact with PDE4D5 in a mutually exclusive manner. Overlay studies with PDE4D5 scanning peptide array libraries showed that RACK1 and beta-arrestin interact at overlapping sites within the unique N-terminal region of PDE4D5 and at distinct sites within the conserved PDE4 catalytic domain. Screening scanning alanine substitution peptide arrays, coupled with mutagenesis and truncation studies, allowed definition of RACK1 and beta-arrestin interaction sites. Modelled on the PDE4D catalytic domain, these form distinct well-defined surface-exposed patches on helices-15-16, for RACK1, and helix-17 for beta-arrestin. siRNA (small interfering RNA)-mediated knockdown of RACK1 in HEK-293 (human embryonic kidney) B2 cells increased beta-arrestin-scaffolded PDE4D5 approx. 5-fold, increased PDE4D5 recruited to the beta2AR (beta2-adrenergic receptor) upon isoproterenol challenge approx. 4-fold and severely attenuated (approx. 4-5 fold) both isoproterenol-stimulated PKA (protein kinase A) phosphorylation of the beta2AR and activation of ERK (extracellular-signal-regulated kinase). The ability of a catalytically inactive form of PDE4D5 to exert a dominant negative effect in amplifying isoproterenol-stimulated ERK activation was ablated by a mutation that blocked the interaction of PDE4D5 with beta-arrestin. In the present study, we show that the signalling scaffold proteins RACK1 and beta-arrestin compete to sequester distinct 'pools' of PDE4D5. In this fashion, alterations in the level of RACK1 expression may act to modulate signal transduction mediated by the beta2AR.

摘要

环磷酸腺苷(cAMP)特异性磷酸二酯酶PDE4D5可与信号支架蛋白活化C激酶受体(RACK)1和β-抑制蛋白相互作用。双杂交和免疫共沉淀分析表明,RACK1和β-抑制蛋白以互斥的方式与PDE4D5相互作用。使用PDE4D5扫描肽阵列文库进行的覆盖研究表明,RACK1和β-抑制蛋白在PDE4D5独特的N端区域内的重叠位点以及保守的PDE4催化结构域内的不同位点相互作用。筛选扫描丙氨酸取代肽阵列,并结合诱变和截短研究,确定了RACK1和β-抑制蛋白的相互作用位点。以PDE4D催化结构域为模型,这些位点在螺旋15 - 16上形成了RACK1特有的、明确的表面暴露斑块,在螺旋17上形成了β-抑制蛋白特有的表面暴露斑块。在人胚肾(HEK)-293 B2细胞中,通过小干扰RNA(siRNA)介导敲低RACK1,可使β-抑制蛋白支架的PDE4D5增加约5倍,在异丙肾上腺素刺激后,募集到β2肾上腺素能受体(β2AR)的PDE4D5增加约4倍,同时严重减弱(约4 - 5倍)异丙肾上腺素刺激的β2AR蛋白激酶A(PKA)磷酸化以及细胞外信号调节激酶(ERK)的激活。通过阻断PDE4D5与β-抑制蛋白相互作用的突变,消除了无催化活性形式的PDE4D5在放大异丙肾上腺素刺激的ERK激活方面发挥显性负效应的能力。在本研究中,我们表明信号支架蛋白RACK1和β-抑制蛋白竞争隔离不同“池”的PDE4D5。通过这种方式,RACK1表达水平的改变可能会调节由β2AR介导的信号转导。

相似文献

5
Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.
J Biol Chem. 2009 Jun 12;284(24):16170-16182. doi: 10.1074/jbc.M109.008078. Epub 2009 Apr 16.
9
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):940-5. doi: 10.1073/pnas.262787199. Epub 2003 Jan 27.
10

引用本文的文献

1
Quantification and structure-function analysis of calpain-1 and calpain-2 protease subunit interactions.
J Biol Chem. 2025 May 16;301(6):110243. doi: 10.1016/j.jbc.2025.110243.
2
Phosphodiesterase 4D activity in acrodysostosis-associated neural pathology: too much or too little?
Brain Commun. 2024 Jun 29;6(4):fcae225. doi: 10.1093/braincomms/fcae225. eCollection 2024.
3
Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury.
Expert Opin Ther Targets. 2024 Jul;28(7):545-573. doi: 10.1080/14728222.2024.2369590. Epub 2024 Jun 19.
5
Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins.
J Mol Cell Cardiol. 2022 Apr;165:86-102. doi: 10.1016/j.yjmcc.2022.01.001. Epub 2022 Jan 6.
7
The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis.
Oncogene. 2021 Mar;40(12):2243-2257. doi: 10.1038/s41388-021-01704-w. Epub 2021 Mar 1.
10
Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
Nat Rev Drug Discov. 2019 Oct;18(10):770-796. doi: 10.1038/s41573-019-0033-4. Epub 2019 Aug 6.

本文引用的文献

1
Keynote review: phosphodiesterase-4 as a therapeutic target.
Drug Discov Today. 2005 Nov 15;10(22):1503-19. doi: 10.1016/S1359-6446(05)03622-6.
4
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Curr Opin Pharmacol. 2005 Jun;5(3):238-44. doi: 10.1016/j.coph.2005.04.001.
5
Transduction of receptor signals by beta-arrestins.
Science. 2005 Apr 22;308(5721):512-7. doi: 10.1126/science.1109237.
6
Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes.
Curr Opin Cell Biol. 2005 Apr;17(2):129-34. doi: 10.1016/j.ceb.2005.01.003.
7
beta-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids.
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3034-9. doi: 10.1073/pnas.0406632102. Epub 2005 Feb 17.
8
Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
Pulm Pharmacol Ther. 2005;18(1):9-17. doi: 10.1016/j.pupt.2004.09.027.
9
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Structure. 2004 Dec;12(12):2233-47. doi: 10.1016/j.str.2004.10.004.
10
AKAP signalling complexes: focal points in space and time.
Nat Rev Mol Cell Biol. 2004 Dec;5(12):959-70. doi: 10.1038/nrm1527.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验